A Monte Carlo simulation approach to the characterization of uncertainties in cancer staging and radiation treatment decisions

Journal of the Operational Research Society

Volumn 58, Issue 2, 2007, Pages 177-185

  Ekaette, E ^a   Lee, R C ^a,b,c,e   Kelly, K L ^d   Dunscombe, P ^a,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b Calgary Health Technology Implementation Unit   (Canada)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

^d Alberta Cancer Board   (Canada)

^e FOOTHILLS HOSPITAL   (Canada)

Author keywords

Decision analysis; Medicine; Probability; Rsk; Simulation

Indexed keywords

COMPUTER SIMULATION; DECISION THEORY; INFORMATION ANALYSIS; MEDICINE; ONCOLOGY; PATIENT TREATMENT; PROBABILITY DISTRIBUTIONS; RADIOTHERAPY;

CANCER STAGING; NON TRIVIAL PROBABILITY; TREATMENT ERRORS; VALUE OF INFORMATION ANALYSES;

MONTE CARLO METHODS;

EID: 33846852849     PISSN: 01605682     EISSN: 14769360     Source Type: Journal    
DOI: 10.1057/palgrave.jors.2602269     Document Type: Conference Paper

References (43)

1. Alderson PO et al (1983). Computed tomography, ultrasound, and scintigraphy of the liver in patients with colon or breast carcinoma: a prospective comparison. Radiology 149: 225-230.
2. Bruneton JN et al (1997). Etiologic diagnosis of hepatic lesions in cancer patients. Value of ultrasound and liver function tests. Clin Imaging 21: 366-371.
3. Ciatto S et al (1985). Staging breast cancer-screening for occult metastases. Tumori 71(4): 339-344.
4. D'Alessandro R et al (2001). Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Res Treat 68: 9-19.
5. de Brauw LM et al (1991a). Hepatic metastases: comparative study of diagnostic ultrasound, CT, nuclear scintigraphy and laboratory tests. Neth J Surg 43: 92-94.
6. de Brauw LM et al (1991b). Prospective comparative study of ultrasound, CT-scan, scintigraphy and laboratory tests to detect hepatic metastases. J Nucl Biol Med 35: 131-134.
7. del Rocio Estrada-Sanchez G, Mireles Enriquez M and Valverde Castaneda N (2003). Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases. Rev Invest Clin 55: 412-418.
8. Donegan WL and Spratt JS (2002). Cancer of the Breast (USA). Saunders-Elsevier Science: St Louis, MO.
9. Dowie J (1996). 'Evidence-based', 'cost-effective' and 'preference-driven' medicine: decision analysis based medical decision making is the pre-requisite. J Health Serv Res Policy 1: 104-113.
10. Engelhard K et al (2004). Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 14: 99-105.
11. Fisher B et al (2002a). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16): 1233-1241.
12. Fisher B et al (2002b). Tamoxifen, radiation therapy or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20: 4141-4149.
13. Forrest AP et al (1996). Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet 348(9029): 708-713.
14. Gallowitsch HJ et al (2003). F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 38: 250-256.
15. Guadagni F et al (2001). A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 7: 2357-2362.
16. Helton JC and Davis FJ (2002). Illustration of sampling-based methods for uncertainty and sensitivity analysis. Risk Anal 22: 591-622.
17. Hou MF et al (1999). Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci 15: 520-528.
18. Hunink M et al (2001). Deciding when to test. In: Hunink M. Decision Making in Health and Medicine, Integrating Evidence and Values. Cambridge University Press: Cambridge: UK. pp 157-176.
19. Karmen C et al (1984). Measurement of biliary alkaline phosphatase by mini-column chromatography and by electrophoresis and its application to the detection of liver metastases in patients with breast cancer. J Clin Pathol 37: 212-217.
20. Kim NK et al (1977). Value of alkaline phosphatase, 5′-nucleotidase, gamma-glutamyltransferase, and glutamate dehydrogenase activity measurements (single and combined) in serum in diagnosis of metastasis to the liver. Clin Chem 23: 2034-2038.
21. Kokko R, Hakama M and Holli K (2003). Role of chest X-ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Res Treat 81: 33-39.
22. Kronz JD, Wesira WH and Epstein JI (1999). Mandatory second opinion surgical pathology at a large referral hospital. Cancer 86(11): 2426-2435.
23. Lacic M et al (1999). Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer. Nucl Med Commun 20: 135-143.
24. Lauro S et al (1999). Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 19: 3511-3515.
25. Lee RC and Wright WE (1994). Development of human exposure factor distributions using maximum-entropy inference. J Expos Anal Environ Epi 4: 329-341.
26. McGarrity TJ, Samuels T and Wilson FA (1987). An analysis of imaging studies and liver function tests to detect hepatic neoplasia. Digest Dis Sci 32(10): 1113-1117.
27. Morgan MG and Henrion M (1990). Uncertainty: A Guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis. Cambridge University Press: Cambridge.
28. Ohta M et al (2001). Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22: 875-879.
29. Parmigiani Q (2002). Measuring uncertainty in complex decision analysis models. Stat Methods Med Res 11: 513-537.
30. Prior JO et al (2003). The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer. Nucl Med Commun 24(1): 29-36.
31. Ravaioli A et al (2002). Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 72: 53-60.
32. Reale MG et al (1995). Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer. Int J Biol Markers 10: 42-46.
33. Ritzke C et al (1998). Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases. Anticancer Res 18: 1243-1249.
34. Russell S and Norvig P (1995). Uncertainty. Artificial Intelligence: A Modern Approach. Prentice-Hall Inc.: Upper Saddle River, NJ, pp 415-431.
35. Schattevoel WH, Corstens FH, Beex LA and Rosenbusch GJ (1986). Reliability of sonography in diagnosing liver metastases in breast and bronchial cancer. A retrospective comparison of physical examination, laboratory tests and liver scintigraphy. Ultraschall Med 7: 293-299.
36. Spanu A et al (2003). The role of (99m)Tc-tetrofosmin pinhole-SPECT in breast cancer non palpable axillary lymph node metastases detection. Q J Nucl Med 47: 116-128.
37. Staradub VL et al (2002). Changes in breast cancer therapy because of pathology second opinions. Ann Surgical Oncol 9(10): 982-987.
38. Tempero MA, Williams CA and Anderson JC (1986). The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. J Clin Oncol 4: 1074-1078.
39. Torres M et al (1995). CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA. Int J Biol Markers 10: 94-99.
40. Vizcarra E et al (1996). Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 37: 209-216.
41. Waalkes TP et al (1982). Biological markers as an aid in the clinical management of patients with liver metastases. J Surg Oncol 20: 83-94.
42. Weinstein MC et al (1980). Clinical Decision Analysis. W.B. Saunders Company: London.
43. Wojtacki J et al (2001). Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases. Przegl Lek 58: 498-503.